Sanofi (SNYNF, SNY) said the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and ...

20% of patients had a best clinical response of SD Elotuzumab (HuLuc63), a humanized mAb CS1 High expression on the surface of MM cell lines and on plasma cells from MM patients 24 ADCC against MM ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

Multiple myeloma is a rare type of blood cancer that forms in plasma cells, a white blood cell that makes antibodies and helps you fight infection. The cancer occurs when the plasma cells inside ...

Multiple myeloma (MM) is a malignant plasma cell disorder ... and the proteasome inhibitor bortezomib. [1] IMiDs are structural and functional analogs of thalidomide that have potent ...

GSK continues to build the case for its multiple myeloma therapy Blenrep ... to Darzalex given on top of Takeda’s Velcade (bortezomib) plus dexamethasone (BorDex) as second-line therapy.

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen alongside bortezomib, lenalidomide, and dexamethasone (VRd), for ...

The new approvals are a continuation of researchers’ efforts to find combinations of different therapies that can lead to ...

Cancer treatment is undergoing a revolution, and immunotherapy is leading the charge. Unlike traditional methods like ...

Cancer is now the second leading cause of death worldwide, and rates are climbing-especially in younger adults. Breast, ...

The new Insta360 Flow 2 Pro introduces the company’s upgraded Deep Track 4.0 AI tracking technology that can now track multiple people while also providing more flexibility in how tracked ...